Table 2.
A. Overall Survival | ||||||
---|---|---|---|---|---|---|
Main Variable | Unadjusted model | Adjusted for Incomea | Adjusted for Patient, Disease and Tx Charb | Adjusted for Patient, Disease and Tx Char and Incomea,b | ||
Urban | 1.00 | 1.00 | 1.00 | 1.00 | ||
Rural | 1.09 (1.01–1.18) | 1.00 (0.92–1.09) | 1.08 (1.00–1.17) | 1.01 (0.93–1.10) | ||
p=0.02 | p=0.99 | p=0.05 | p=0.75 | |||
B. Treatment-related mortalityc | ||||||
Main Variable | Unadjusted model | Adjusted for Incomea | Adjusted for Patient, Disease and Tx Charb | Adjusted for Patient, Disease and Tx Char and Incomea,b | ||
Urban | 1.00 | 1.00 | 1.00 | 1.00 | ||
Rural | 1.08 (0.98–1.18) | 0.98 (0.88–1.08) | 1.08 (0.98–1.18) | 1.00 (0.91–1.11) | ||
p=0.10 | p=0.66 | p=0.11 | p=0.94 |
Income entered as quartiles: <$34,700, 34,700–43,600, 46,600–56,300, >$56,300
Adjusted for graft type and cell dose, HLA-match, patient age, disease type, disease stage, number of co-morbidities, CMV donor-recipient match, race/ethnicity, and year of transplant
Model stratified for Karnofsky performance score